Evidence map›Paper›PMID 37016170›Full record

ArticlePharmaceutical research2023

Zinc Oxide Nanoparticles Promise Anticancer and Antibacterial Activity in Ovarian Cancer.

Ahmed Bakr Mousa, Raghda Moawad, Yasmine Abdallah, Mazen Abdel-Rasheed, Azza M Abdel Zaher

Open access · hybridAbstract read
In one paragraph

Article in Pharmaceutical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The effect of biosynthesized zinc oxide nanoparticles on gene expression and apoptosis in triple-negative breast cancer cells.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. Biosynthesis ofACS omega · 2023
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ahmed Bakr MousaObstetrics and Gynaecology Department, Faculty of Medicine, Minia University, Minia, Egypt.
Raghda MoawadDairy Department, Faculty of Agriculture, Minia University, Minia, Egypt.
Yasmine AbdallahPlant Pathology Department, Faculty of Agriculture, Minia University, Minia, Egypt.
Mazen Abdel-RasheedReproductive Health Research Department, National Research Centre, 33 El-Buhouth St, Cairo, 12622, Dokki, Egypt. doctor_mazen@hotmail.com.ORCID http://orcid.org/0000-0001-5575-1782
Azza M Abdel ZaherPathology Department, Faculty of Medicine, Minia University, Minia, Egypt.
Minia University · EGNational Research Centre · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOvarian cancer is the most lethal cancer in gynaecology. Surgery, chemotherapy, and radiotherapy are the most often used cancer-fighting strategies. Post-surgery infection is fairly prevalent, especially among people with insufficient immunity. Zinc oxide nanoparticles (ZnOnps) have amazing biomedical features as anticancer and antibacterial agents.

methodsWe investigated the behaviour of ZnOnps synthesized by green methods on ovarian cancers using established human ovarian cancer cell lines, besides the antibacterial action toward models of gram + ve and gram -ve bacteria. The cytotoxic effect of ZnOnps was calculated using a Sulforhodamine B (SRB) trial. Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) were tested as models for gram + ve and gram -ve bacteria. The selected bacteria were subjected to concentrations of 20, 40, 80, and 100 μg/ml.

resultsThe synthesized ZnOnps induced 50% inhibitory concentration (IC50) at a concentration of 27.45 μg/ml. The diameter of inhibition ranged between 20.16 ± 0.16 and 27 ± 0.57 mm for S. aureus and 25.66 ± 0.33 to 31 ± 0.33 mm for E. coli. ZnOnps antagonistic effect statistically differed with neomycin, cefaclor, and cefadroxil.

conclusionsGreen synthesis of ZnOnps is easily prepared, low cost, non-toxic, and eco-friendly. Their cytotoxic action on SKOV3 cells and their antibacterial characteristics pave the way to be an alternative therapy for ovarian cancer and S. aureus and E. coli infection.

Indexed as

Antineoplastic AgentsMetal NanoparticlesNanoparticlesOvarian NeoplasmsZinc OxideAnti-Bacterial AgentsEscherichia coliFemaleHumansStaphylococcus aureusAnti-Bacterial AgentsAntineoplastic AgentsZinc Oxideantibacterial activityanticancerlow costnon-toxicovarian cancerzinc oxide nanoparticles

Identifiers

PMID37016170
PMCPMC10072921
OpenAlexW4362543959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.